Patent Board Denies Mylan Bid For Review Of Taxoid Patent

(August 24, 2016, 12:59 PM EDT) -- ALEXANDRIA, Va. — Assertions that an Aventis Pharma S.A. patent is invalid as obvious under 35 U.S. Code Section 103 were rejected Aug. 23 by the Patent Trial and Appeal Board, which turned away a petition for inter partes review by Mylan Inc. (Mylan Inc. v. Aventis Pharma S.A., No. IPR2016-00627, PTAB).

(Decision available. Document #16-160906-017Z.)

Aventis has asserted its U.S. patent No. 5,847,170 in several lawsuits still pending in the U.S. District Court for the District of New Jersey, including Sanofi-Aventis U.S. LLC, Aventis Pharma...
To view the full article, register now.